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Introduction
The proteasome is an essential component of the cellular protein degradation machinery. The greater dependence of cancer cells on the proteasome to remove aberrant proteins compared with nonmalignant cells, as well as the reliance of various tumors on the proteasome-dependent NF-κB activation pathway to maintain resistance to apoptosis, makes cancer cells selectively more susceptible to proteasome inhibitors (1) . Bortezomib (Velcade/PS-341) is a dipeptidyl boronate proteasome inhibitor that has been approved by the US Food and Drug Administration for the treatment of multiple myeloma (2) and mantle cell lymphoma (3) and its use has been extended to advanced stage non-small cell lung cancer (4) . As shown by us and others, Bortezomib sensitizes solid tumor cells to TRAIL or its receptor agonist mAb by amplifying tumor cell caspase-8 activation in the death-inducing signaling complex following death receptor ligation (5) (6) (7) (8) . However, as a single agent bortezomib is ineffective in most solid cancers, and there are concerns in combining bortezomib with adoptive T-cell therapy because of reports purporting immunosuppressive actions of bortezomib (9, 10) . Indeed, concerns over the possible side effects of bortezomib on immune effector functions have been raised recently (11) (12) (13) (14) (15) . On the other hand, there are a number of reports indicating that bortezomib either directly or indirectly can play a positive therapeutic role in amplifying immune antitumor effector functions (16) (17) (18) (19) (20) (21) (22) .
Nonetheless, to date there has been no systematic study of the effects of bortezomib on adoptive cellular immunotherapy (ACT) in mouse preclinical cancer models in vivo.
Studies using the influenza viral hemagglutinin (HA) expressed as a model tumor antigen (Ag) in a renal cell carcinoma (RencaHA), as well as a self-Ag in pancreatic islet β-cells in insulin-HA transgenic mice, showed that host T-cells could react to a self low-avidity epitope of HA and reject HA-expressing tumor cells without inducing autoimmune diabetes (23) . Taking advantage 5 of this low-avidity model antigen and the availability of MHC class I and II-restricted HAspecific T-cell receptor (TCR)-transgenic Cln4 and 6.5 +/+ mice, respectively (23, 24) , we investigated the effects of bortezomib administration on T-cell responses in an adoptive T-cell transfer setting in mice with established renal RencaHA or mammary 4T1.2HA adenocarcinoma tumors. We compared the effects in two distinct in vivo protocols, one tumor therapeutic regimen of bortezomib (Bzb-T) standardized by us earlier(7) with another known suppressive regimen of bortezomib (Bzb-S) close to the maximal tolerated levels for this drug. The suppressive Bzb-S regimen was adapted from Sun et al's study, where bortezomib suppressed acute lethal graft-versus-host (GVHD) response in myeloablated mice following allogenic bone marrow transfer (10) .
Surprisingly, adoptive T-cell transfer followed by bortezomib administration resulted in reduced numbers of lung metastatic tumor nodules and enhanced survival of tumor-bearing mice when compared with either treatment alone. The therapeutic regimen of bortezomib we used in this study had no major effect on the number of CD4 were maintained in FCS-supplemented standard RPMI-1640 culture medium. We regularly go back to reference stocks to ensure fidelity; routine sterility and mycoplasma testing are performed regularly. Low-passage (< 5) tumor cell cultures were used for the experiments. They were washed and injected intravenously in tumor-bearing RAG2 -/-mice. In some experiments, a hamster neutralizing antibody to FasL (MFL4) or a control isotype antibody (UC8-1B9) (generated at Juntendo University, Japan) was injected i.v. at 0.5 mg/mouse on days 7 and 10 following injection of RencaHA cells.
Immunoblotting
CD8
+ T cells were purified from splenocytes by incubating cells with rat anti-mouse CD8 mAb, followed by positive selection of CD8 + cells with anti-rat IgG Microbeads (Miltenyi Biotec) and cell pellets were lysed in complete lysis buffer including protease and phosphatase inhibitors.
Nuclear and cytoplasmic extracts were prepared using Ne-per nuclear and cytoplasmic extraction reagent (Life Technologies). Fifty micrograms of each protein sample was electrophoresed on NuPage 4-12% Bis-Tris gel (Novex Life Technologies) and transferred to 8 polyvinylidenedifluoride membranes using an iBlot® Dry Blotting system (Life Technologies).
The membrane was then blocked in 5% skimmed milk in 1X PBS-Tween-20 (1X PBST) for 2 h at room temperature with gentle agitation. After blocking, the blots were incubated with rabbit anti-mouse antibodies against total and phosphorylated protein of p65 (Total D14E12; Phospho S468; Cell Signaling) in 1% BSA (in 1X PBST) overnight at 4°C with gentle agitation. After five washes of 5 minutes each in 1X PBST, blots were incubated with goat anti-rabbit horseradish peroxidase (Santa Cruz Biotechnology, CA) at a dilution of 1:4000 in 1X PBST for 1.5 h, with agitation. The blots were rinsed again in 1X PBST, and developed by using chemiluminescence reagent (Millipore, MA) and a Kodak Image Station (Kodak, Rochester, NY). The blots were then stripped and probed with HRP conjugated anti-GAPDH antibody (Cell Signaling Technologies, MA) to determine equivalent loading.
Immunohistochemistry. The immunohistochemical analyses of murine RencaHA solid tumors, thymus, or lungs were performed according to standard methods (27) . Digital images of the specimens were captured using Spectrum image software (Aperio Technologies, Inc., Vista, CA). For human melanoma tissues embedded in paraffin, 6-μm-thick sections were cut, deparaffinized and hydrated before treating for antigen retrieval with sodium citrate buffer for 20 min. Lab Vision Autostainer360 was used for staining using Ultravision Quanto Detection System HRP DAB kit (#TL-060-QHD). In brief, tissues were treated with peroxidase followed by UV block before treating with primary anti-human/mouse CD95/FAS (LS-B6851/33954) at 1:200 for 45 min. Tissues were then treated with labeled horse radish peroxidase and stained with 3,3'-diaminobenzidine for 5 min. Counter staining was done with Hematoxylin, dehydrated and mounted in cytoseal. For negative control, tissues were stained with isotype IgG. 
Statistics. Comparisons of mean values between the groups were analyzed using GraphPad
Instat software (GraphPad Prism). Statistical significance of the differences was analyzed by using unpaired Student t test or by analysis of variance (ANOVA). Comparisons of survival curves estimated by Kaplan-Meïer plots using GraphPad Prism were performed by the log-rank (Mantel-Cox) test. All statistical tests were two-sided, with p-values < 0.05 considered statistically significant.
Results
Effects of therapeutic and suppressive regimens of bortezomib on endogenous leukocyte numbers
We have previously reported that the proteasome inhibitor bortezomib (Velcade/PS-341) sensitizes solid tumors, such as renal or mammary adenocarcinoma cells to apoptosis in response 12 to TNF-family death ligands or TRAIL receptor agonist mAb by amplifying caspase 8 activation in the death-inducing signaling complex, which translates into a survival benefit in tumorbearing mice (7, 8) . To address concerns over the possible side effects of bortezomib on immune functions, we tested two in vivo protocols with opposite effects on tumor burden and survival.
The low intensity tumor therapeutic regimen of bortezomib, Bzb-T, given twice a week (7) was compared with a previously described suppressive regimen of bortezomib, Bzb-S, given four times a week close to the maximal tolerated levels that suppressed acute lethal GVHD response in myeloablated mice following allogenic bone marrow transfer (10) . Proteasome activity was determined following bortezomib administration as per the two regimens (Fig 1A) in WT mice injected with RencaHA tumor cells subcutaneously. At 4 h after last bortezomib administration, the cellular proteasome activity in spleen, tumor-draining LN and tumor mass was reduced by 60% in the therapeutic protocol and 80-90% in the suppressive protocol (Fig 1B) . A similar level of proteasome inhibition was observed in the cell preparations of lungs at 4 h after treatments, with no inhibition apparent in the tissues tested after 18 h (data not shown). Further, the Bzb-T regimen had no significant effects either on total leukocyte counts in control or tumor-draining LN, tumor-infiltrating lymphocytes, and spleen, or in subsets of CD4 on day 13 at 4 h after last bortezomib injection. In contrast, the suppressive Bzb-S regimen resulted in a leukocytopenia (Fig 1C, D, E) , which may explain why bortezomib given at the time of allogeneic bone marrow transfer in mice attenuates acute GVHD (10).
Effect of bortezomib treatment on antigen presentation in vitro and in vivo
Since activity of the cellular proteasome is required to process antigens for presentation to Tcells, we assessed whether bortezomib might affect the ability of antigen-presenting cells to Fig 2C) despite the 60-80% cellular proteasome inhibition (Fig 1) . We observed a decreased yield of (Fig 2E) . It is important to note that even though the residual numbers of CD11c high CD8 high DC are low following the suppressive Bzb-S regimen, they showed no decrease in the relative level of expression of CD80, CD86 and CD40 molecules (Fig 2D) , and no apparent decrease in CD4 + or CD8 + T cell proliferation following the Bzb-S regimen (Fig 2C) . Thus, the effects of bortezomib appear merely quantitative and do not have a bearing on the maturation or antigen processing by Fig 1) . This immunosuppressive effect resulted in increases in the number of lung metastases following the injection of RencaHA cells even 4 or 7 days after treatment with the Bzb-S regimen (Supplementary Fig 2) . These data suggest that even though the suppressive Bzb-S regimen By contrast, the therapeutic Bzb-T regimen had no observable effects on lung metastases even when administered immediately after RencaHA injection ( Supplementary Fig 1 and 2) .
Moreover, we also observed that tumor cells treated with bortezomib in vitro exhibit higher expression of calreticulin (Supplementary Fig 3) . Increased cell surface calreticulin expression on tumor cells after bortezomib exposure could indicate "immunogenic cell death" so as to facilitate antigen uptake and presentation by DCs. These findings predict that the dose and regimen of bortezomib treatment is critical in deciding the outcome of antitumor immune response. Therefore, only the Bzb-T regimen was used in subsequent adoptive T-cell transfer experiments.
Sustained T-cell function in vivo following bortezomib treatment
We next investigated effects of bortezomib specifically on functional parameters of T-cell T-cells were transferred on day 6, followed by the Bzb-T regimen, and analyzed at 4 h or 24 h after last bortezomib treatment on day 9 as per the indicated scheme (Fig 3A) . Following Bzb-T regimen, there was no statistically significant change in the total yield of K (Fig 3B) . A similar proliferation pattern was observed for HA-specific (Fig 4A) . We also assessed immune cell viability by performing 7AAD staining along with CD3 or CD11c. Data reveal no increase in 7AAD + cells either in CD3 or CD11c subsets, suggesting no loss of cell viability following the therapeutic Bzb-T regimen in the wild-type mice (Fig 4B) . These data suggest that there is no suppression of endogenous T-cell response either in the monoclonal or polyclonal T-cell environment by the tested therapeutic regimen of bortezomib. Rather, it is evident that proteasome inhibition by bortezomib stabilizes the T-cell receptor CD3ζ, and thereby sustains the T-cell activation signals.
To determine any effect of bortezomib on the cytotoxic function of activated T-cells, we 
observed by CTLs in bortezomib-administered mice (Fig 4C) . To further elaborate on the underlying mechanisms of the observed T-cell effects, we investigated the influence of bortezomib on NFκB activation downstream of CD3ζ signaling. NFκB is a "rapid-acting" primary transcription factor that does not require new protein synthesis in order to become activated and act as first responder in regulating various genes responsible for both the innate and adaptive immune cell proliferation and effector function. Purified CD8 + T cells treated in vitro with bortezomib (10 nM) for 4 h showed an increase in the phosphorylation of p65 in both nuclear and cytoplasmic fractions (Fig 4D) , suggesting that bortezomib promotes NFκB activation in T-cells. Taken together, these data show that bortezomib has no discernible immunosuppressive consequences on T-cell function in vivo following the tested Bzb-T regimen in contrast to in vitro studies on human myeloid dendritic cells and NK cells (9, 12, 14) . (Fig 5A, C) . No difference in the immunohistological staining for CD3 was seen in lung tumor nodules following T N cell transfer in the presence or absence of bortezomib treatment (Fig 5B) (Fig 5A and 6A) . TCRHA CD8 T N cell transfer reduced the nodule count to a mean of 144 ± 103 per mouse. The tumor nodule count was further significantly reduced to a mean of just 25 ± 34 when bortezomib was administered 3 days after T N cell transfer (Fig 5A and 6A) . Interestingly, a 3-week therapy regimen of bortezomib post T N cell transfer, similar to the combination regimen of bortezomib and TRAIL receptor agonist mAb we used previously (7), significantly enhanced survival with 40% of mice still alive after a 90-day observation period (Fig 5C) .
Immunohistochemical analyses of lungs from mice treated with bortezomib alone or saline showed numerous large tumor nodules with prominent proliferating cell nuclear antigen (PCNA) staining in contrast to lungs from tumor-bearing mice treated with T N cells or a combination of T N cells and bortezomib (Fig 6A) . Moreover, increased apoptosis as evaluated by TUNEL staining was observed in lungs of tumor-bearing mice treated with a combination of T N cells and bortezomib compared with other groups (Fig 6B) . We speculate that increased apoptosis at the site of tumor may increase the availability of tumor antigens, and thus enhance tumor control by T-cell therapy as observed in our combination regimen. We also tested whether the observed therapeutic effect could be ascribed to bortezomib's influence on tumor vasculature and stromal bearing mice treated with bortezomib, the global architecture of the tumor looked different, suggesting some effects on tumor vasculature following bortezomib regimen (Fig 6C) .
Bortezomib improves T-cell therapy by sensitizing tumors to the FasL lytic pathway
Although we observed a stabilized expression of MHC molecules on RencaHA tumor cells ex vivo from mice administered with the Bzb-T regimen, the expression of Fas receptor on MHC-I K d+ tumor cells increased from 67% to 96% in mice treated with Bzb-T regimen when compared with untreated mice (Fig 7A) . We also noted that various tumor cells including RencaHA, breast 4T1, colon C26, and lymphoma A20 that showed upregulated Fas expression following overnight treatment with bortezomib (20 nM) in vitro (data not shown), all exhibited enhanced sensitivity to lysis by recombinant FasL molecules (Fig 7B) . Moreover, these tumor cells were (Fig 7D) , even though different CTL produced similar amounts of IFNγ (data not shown). These results suggest that the FasL pathway is critical for tumor clearance following bortezomib administration in those tumors that express Fas. Indeed, therapeutic benefit of the combination of adoptive TCRHA T N cell transfer and bortezomib was almost completely blocked by the administration of a FasL-neutralizing antibody in the RencaHA model (Fig 7E) . We also noted upregulated Fas expression in human melanoma tissue (Fig 7F) from one responding advanced-stage (III or IV) metastatic melanoma patient, who showed a partial response of 8 months following treatment with a combination of an alkylating drug temozolomide and bortezomib in a phase I clinical trial (26) .
Discussion
We investigated the effects of bortezomib administration on adoptive T-cell transfers in treated tumor cells can generate tumor-specific CD8 T-cells. In addition, dendritic cells that were treated with bortezomib in vitro showed increased maturation, which resulted in potent immunemediated antitumor effects (18) . It is also reported that bortezomib induces apoptosis in immature DCs, but to a much lesser extent in mature DCs (35) . Bortezomib enhanced antigenspecific cytotoxic T-cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells (36) . Also, bortezomib could restore MART-1 antigen expression on human melanoma cells to sensitize them to specific CTLs in vitro (37) . It is worth noting that bortezomib inhibits inducible NFκB activity, but can activate constitutive NF-κB activity by triggering phosphorylation of IκB kinase and its upstream receptor-interacting protein 2, thereby enhancing cytotoxicity in multiple myeloma cells (38) . Our data also suggest that bortezomib DC migratory capabilities were also impaired following bortezomib treatment. Bortezomib was also seen to down-regulate MyD88, an essential adaptor for TLR signaling, and to relieve LPSinduced activation of NF-κB, IRF-3, and IRF-8 and of the MAP kinase pathway, and it was suggested that bortezomib could prove useful for tuning TLR signaling and for the treatment of inflammatory and immune-mediated disorders (39) . It should be noted that in these studies, where bortezomib is deemed immunosuppressive, the concentrations of bortezomib used to derive these findings were high. The majority of these studies used 100-1000 nM concentrations of bortezomib in vitro; doses that cannot be extrapolated to the therapeutic situation in vivo. Only 10-20 nM concentrations of bortezomib are attainable in vivo (41) , and the level of proteasome inhibition that occurs at these concentrations can be tolerated in both mice and humans without appreciable toxicity (42, 43) . 
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Second generation proteasome inhibitors such as carfilzomib (49), or the natural product withanolide E recently identified by us as a potent novel sensitizer of cancer cells to extrinsic apoptosis (50), which exhibit minimal toxic effects as single agents, might be even more therapeutically advantageous in combination with adoptive T-cell transfer. Preclinical studies testing these agents with adoptive T-cell transfer are currently underway. In summary, our study using the preclinical cancer models has provided both a molecular basis and a translationallyrelevant proof of principle that the therapeutic combination of adoptive T-cell therapy with agents that sensitize cancer cells to apoptosis may further improve responses to adoptive T-cell transfer. 
